Monmouth Junction, NJ, United States of America

Jocelyn Rivera




Average Co-Inventor Count = 13.0

ph-index = 3

Forward Citations = 61(Granted Patents)


Company Filing History:


Years Active: 2005-2014

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Innovations of Jocelyn Rivera

Introduction

Jocelyn Rivera is a prominent inventor based in Monmouth Junction, NJ (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit cyclin dependent kinases. With a total of seven patents to her name, Rivera's work has the potential to impact the treatment of various diseases.

Latest Patents

Among her latest patents, Rivera has developed substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors. This invention provides a method for inhibiting cyclin dependent kinases in patients by administering a therapeutically effective amount of pyrazolo[1,5-a]pyrimidine compounds. Additionally, she has introduced a novel class of N-heteroaryl pyrazolopyrimidines as inhibitors of cyclin dependent kinases, which includes methods for preparing these compounds and pharmaceutical compositions for treatment.

Career Highlights

Throughout her career, Jocelyn Rivera has worked with notable companies such as Schering Corporation and Pharmacopeia Drug Discovery, Inc. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in drug discovery and development.

Collaborations

Rivera has collaborated with esteemed colleagues, including Timothy J Guzi and Kamil Paruch. These partnerships have fostered innovation and have been instrumental in advancing her research endeavors.

Conclusion

Jocelyn Rivera's contributions to the field of pharmaceuticals through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…